Compounds > fludarabine

fludarabine and oligonucleotides

fludarabine has been researched along with oligonucleotides in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (40.00)18.2507
2000's1 (20.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Alfinito, F; Bonelli, P; Chiurazzi, F; Costantini, S; Defrance, T; Lamberti, A; Romano, MF; Tassone, P; Tuccillo, F; Turco, MC; Venuta, S1
Li, MJ; Yang, LY1
de Frutos, MA1
Cook, H; Datto, M; Daugherty, FJ; Davis, PH; DeCastro, CM; Diehl, LF; Friedman, DR; Gockerman, JP; Lanasa, MC; Li, Z; Matta, KM; Moore, JO; Rehder, C; Rizzieri, D; Weinberg, JB1
Aloyz, R; Assouline, SE; Autexier, C; Chu, TW; Gryaznov, SM; Johnston, JB; Lees-Miller, SP; Martinez-Marignac, V; Shawi, M; Yu, Y1

Other Studies

5 other study(ies) available for fludarabine and oligonucleotides

ArticleYear
Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells.
    Blood, 1998, Aug-01, Volume: 92, Issue:3

    Topics: Antibodies, Monoclonal; Apoptosis; CD40 Antigens; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; Neoplastic Stem Cells; NF-kappa B; Oligonucleotides; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-rel; Transcription, Genetic; Tumor Cells, Cultured; Vidarabine

1998
Use of novel plasmid constructs to demonstrate fludarabine triphosphate inhibition of nucleotide excision repair of a site-specific 1,2-d(GpG) intrastrand cisplatin adduct.
    International journal of oncology, 1999, Volume: 15, Issue:6

    Topics: Adenosine Triphosphate; Antineoplastic Agents; Base Sequence; Binding Sites; Cisplatin; DNA; DNA Adducts; DNA Repair; DNA, Recombinant; Dose-Response Relationship, Drug; Humans; Molecular Sequence Data; Oligonucleotides; Plasmids; Substrate Specificity; Tumor Cells, Cultured; Vidarabine

1999
[Lupus nephritis: treatments for today and tomorrow].
    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2001, Volume: 21, Issue:6

    Topics: Adrenal Cortex Hormones; Animals; Antibodies, Monoclonal; Bone Marrow Transplantation; CD40 Ligand; Cladribine; Drug Administration Schedule; Drug Therapy, Combination; Forecasting; Humans; Immunosuppressive Agents; Lupus Nephritis; Mycophenolic Acid; Oligonucleotides; Plasmapheresis; Vidarabine

2001
Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:2

    Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Oligonucleotides; Prognosis; Risk Factors; Rituximab; Survival Rate; Tumor Suppressor Protein p53; Vidarabine

2012
Telomerase contributes to fludarabine resistance in primary human leukemic lymphocytes.
    PloS one, 2013, Volume: 8, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Catalytic Domain; Chromosome Deletion; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; DNA Helicases; Drug Resistance, Neoplasm; Enzyme Activation; Gene Expression Regulation, Leukemic; Histones; Humans; Indoles; Ku Autoantigen; Leukemia, Lymphoid; Middle Aged; Niacinamide; Oligonucleotides; Phosphorylation; Protein Binding; Telomerase; Vidarabine

2013